News

A full approval has been granted to pembrolizumab by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors.

In an interview, Krisda Chaiyachati, MD, MPH, discussed some of the social determinants of health for patients with cancer and some of the challenges patients undergoing treatment face, including transportation insecurity.

The inaugural participant with AML showing a mutation of FLT3 in a relapsed/refractory form has been recruited into the Phase 1 FRIDA trial.

According to early results from CheckMate 040, nivolumab plus cabozantinib with or without ipilimumab showed good clinical activity and survival.

At the Society of Gynecologic Oncology 2023 Annual Meeting, data showed that with a median follow-up of 25.8 months, the proportion of patients on Arm A of the NRG-GY017 trial of patients with cervical cancer with 2-year disease-free survival rate was 79% vs 59% in Arm B.

As of March 28, 2023, the partial clinical hold on the phase 1/2 VELA trial, which is evaluating the selective CDK2 inhibitor BLU-222 for patients with solid tumors, has been lifted. Blueprint Medicines has resumed the re-initiation of patient enrollment.

Combination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.

PT886, a novel bispecific antibody which targets claudin 18.2 and CD47, is currently being evaluated in a phase 1 study for patients with gastric, gastroesophageal junction and pancreatic adenocarcinomas.

Andrew Kuykendall, MD, discusses recent approvals seen for patients with myeloproliferative neoplasms.

In the NRG GY018 trial, the addition of pembrolizumab to standard-of-care chemotherapy followed by maintenance pembrolizumab demonstrated a reduction in risk of disease progression or death in patients with advanced or recurrent endometrial cancer.

The FDA released a draft guidance for drug sponsors of clinical trials in oncology, outlining its move toward requiring randomized controlled trials to grant accelerated approvals for most oncology therapeutics.

With little improvement in survival seen for patients with small cell lung cancer, investigators are now assessing novel agents that are shifting the treatment paradigm of extensive disease-small cell lung cancer.

Late-stage clinical trials are evaluating MDM2 inhibitors that target p53 in both solid tumors and hematologic malignancies.

Alexander Drilon, MD, discusses what to know when testing for NTRK gene fusions in patients with lung cancer.

In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit.

In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.

In an interview, Edwin Choy, MD, discussed the treatment landscape of GIST and recent changes to NCCN guidelines.

The phase 1b SOLAR trial which evaluated olaparib plus selumetinib in patients with RAS-mutated ovarian or endometrial cancer showed there to be a clinical benefit with the combination.

Among patients with newly diagnosed, advanced ovarian cancer, dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival.

A correlation in total scores were seen between the gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire, according to findings presented at the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Next-generation CAR T cells, including 1928T2Z and WZTL-002, continue to be investigated for the treatment of patients with large B-cell lymphoma.

The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.

John Diaz, MD, discusses some of the challenges with using targeted therapies in the ovarian cancer space.

Newer approaches for patients with relapsed/refractory multiple myeloma are moving away from chemoimmunotherapy and toward drugs with novel mechanisms of action.

An updated guideline and panel recommends treatment with sacituzumab govitecan for patients with HR-positive/HER2-negative metastatic breast cancer who are refractory to endocrine therapy.

In an interview with Targeted Oncology, Paul Richardson, MD, highlighted his presentation from the 4th Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies on updates and personalization of treatments for patients with multiple myeloma.

A patient who received AB8939, a microtubule inhibitor, in a phase 1 study, had a significant reduction in bone marrow blasts, showing its potential to treat drug-resistant acute myeloid leukemia.

The FDA noted that additional requirements are needed prior to the approval of ruxolitinib extended-release for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease, in a complete response letter.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed relapse after transplant for patients with cancer and what is important to note moving forward with research.